Russell Investments Group
ACTU

Russell Investments Group’s Actuate Therapeutics ACTU Stock Holding History

Russell Investments Group’s Portfolio ACTU Stock Details ACTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.03K Buy
673
+89
+15% +$206 ﹤0.01% 4156
2026
Q1 		$1.6K Buy
584
+97
+20% +$402 ﹤0.01% 4017
2025
Q4 		$2.98K Hold
487
– – ﹤0.01% 3969
2025
Q3 		$3.26K Buy
+487
New +$3.53K ﹤0.01% 3949

Other funds holding ACTU

BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
VC
Voss Capital Houston, Texas $2.15B AUM 33.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
TCBWMS
Texas Capital Bank Wealth Management Services Dallas, Texas $1.87B AUM 24.49% 1-Year Est. Return
PVM
Palogic Value Management Dallas, Texas $304M AUM 15.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ADEF
ABS Direct Equity Fund Stamford, Connecticut $159M AUM 34.17% 1-Year Est. Return

Russell Investments Group's ACTU Position: Q2 2026 in Review

Russell Investments Group increased its Actuate Therapeutics (ACTU) stake by 15% in Q2 2026, buying an estimated $206 and bringing the position to 673 shares worth $1.03K. The position accounts for ﹤0.01% of the portfolio, ranked #4156.

Russell Investments Group first reported a position in ACTU in Q3 2025 and has held it in 4 quarters since. The position peaked at $3.26K in Q3 2025. 64 funds tracked by Wall St. Rank hold ACTU as of Q2 2026.

  • Russell Investments Group held 673 shares of Actuate Therapeutics worth $1.03K as of Q2 2026.
  • Russell Investments Group bought 89 Actuate Therapeutics shares in Q2 2026, an estimated $206.
  • Actuate Therapeutics made up ﹤0.01% of Russell Investments Group's portfolio in Q2 2026, its #4156 holding.
  • Russell Investments Group first reported a position in Actuate Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Russell Investments Group's Actuate Therapeutics position peaked at $3.26K in Q3 2025.
  • 64 funds tracked by Wall St. Rank held Actuate Therapeutics as of Q2 2026.

Based on Russell Investments Group's 13F filing for Q2 2026, filed 6 Aug 2026.